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Oral Presentations S181were ‘‘alive and engrafted’’ mixed-chimerism (.5% recipient) at
latest follow up time point (median 57mths: 6-140) was found in
21%. The highest rate of full donor chimerism was found in uCB
(93%), compared to 73% in MSD, 64% in UD and 75% in TCDud.
Normal enzyme levels at latest follow up time point were found in all
(100%) of the uCB, in 53% of MSD, in 74% of UD and in 75% of
TCDud recipients.
Outcomes following SCT is HS are encouraging. Younger age at
SCT is a predictor for higher OS. Regarding OS, MSD do better
compared to UD and uCB, but no difference was found for EFS.
TCDud is a predictor for lower OS/EFS. uCB leads to higher donor-
chimerism levels and enzymes which is suggested to have a positive
impact on the long term outcomes.69
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AND YOUNG ADULTS (CAYA) WITH POOR RISK HODGKIN’S LYMPHOMA
(HL): INDUCTION OF LONG TERM GVHL EFFECT
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Background: Long-term EFS in CAYA with poor risk HL who
are induction failures or who relapse or progress following initial
therapy is poor (#30% 10 year EFS) due to relapse and secondary
MDS or malignancy (Bradley/Cairo et al., BMT, 2008). Recent
data in poor risk adult HL suggests a strong GVHL effect follow-
ing RIC AlloSCT (Peggs et al., Lancet, 2005 and Sureda et al.,
JCO, 2008). A recent review by the EBMT reports encouraging
results in 51 children and adolescents with chemosensitive HL
who received RIC AlloSCT (Claviez et al., Blood, 2009). How-
ever, 63% of these patients had already failed MAC AutoSCT,
reducing the number of pts who were chemosensitive prior to
RIC AlloSCT.
Objective: We prospectively evaluated the safety and efficacy of
MAC AutoSCT followed by RIC AlloSCT in CAYA with poor-
risk HL.
Methods: Poor-risk HL pts achieving CR, PR, or SD after re-induc-
tion were eligible to receive CBV conditioning (Harris/Cairo, ASH,
2004) followed by RIC with busulfan (6.4 mg/kg), fludarabine
(180 mg/m2)6R-ATG (forunrelated SCT).GVHD prophylaxis con-
sisted of MMF and tacrolimus as we have previously described
(Osunkwo/Cairo et al., BBMT, 2004), with discontinuation of MMF
on day 30/60 (related/unrelated AlloSCT) and a 4-6 week tacrolimus
taper.
Results: Ten pts, median age 18.4 (range 12.3-21.8), M/F 6/4 and
disease status at MAC AutoSCT CR (5), PR (3), SD (2). Two refused
RIC AlloSCT; of the 8 allografts, 1 related/7 unrelated, 5 UCBT/3
PBSC, HLA matching 6/6 (1), 5/6 (1), 4/6 (5), 8/10 (1), median TNC
dose 0.35108/kg (0.09-6.13) and CD34 0.59106/kg (0.04-5.30).
All pts (n5 8) engrafted neutrophils following RIC AlloSCT at
median day 19 (15-45). Six of 7 evaluable pts engrafted platelets at
median day 46 (11-170). The probability of $grade II acute
GVHD was 37.5% (95% CI 0-63%) and of chronic GVHD 30%
(0-58%). Patients achieved median percent donor chimerism of
100%, 100% and 98%, on days 100, 180 and 365, respectively. Prob-
abilities of 1-year and 2-year OS (all, n5 10) were 90% (73-100%)
and 80% (59-100%) respectively. Three pts died on days 338, 370
and 746 of varicella, progressive HL and chronic GVHD/aspergillo-
sis, respectively. Seven pts are currently living at a median follow-up
of 2191 days.
Conclusions MAC AutoSCT followed by RIC AlloSCT for CAYA
with poor-risk HL is feasible and results in excellent early OS. Long-
term follow-up and a larger cohort are needed to determine whether
this approach improves 10-year EFS compared to MAC AutoSCT
alone.70
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Background: Complex autoimmune enteropathies encompass
a wide range of disorders including X-linked immune dysregulation,
polyendocrinopathy, enteropathy (IPEX) syndrome with FOXP3
gene mutation, IPEX-like syndrome (similar features as IPEX with-
out gene mutation) and other unclassified autoimmune enteropa-
thies.
Method: A retrospective study of patients with complex autoim-
mune enteropathies who underwent hematopoeitic stem cell trans-
plantation (HSCT) at Newcastle General Hospital, one of two
nationally designated centres for such procedures in the UK, was
performed.
Results: 13 patients were identified who fulfilled the inclusion crite-
ria; 2 (15%) IPEX, 8 (62%) IPEX-like and 3 (23%) unclassified au-
toimmune enteropathy. Median age at the time of HSCT was 2.5
years, ranged between 5 months to 19.5 years old. 9/13 (69%) pa-
tients were male. All underwent HSCT with 10/13 (77%) unrelated
(URD) including 3 cord transplant, and 3/13 (23%) matched sibling
(MSD). The conditioning regimen used was Fludarabine/Melphalan
in 6 (46.2%), Busulfan/Cyclophosphamide in 3 (23%), Treosulfan/
Cyclophosphamide in 2 (15.4%) and Treosulfan/Fludarabine in 2
(15.4%). 100% donor chimerism was achieved in 10 (77%) patients
including one after the unconditioned boost infusion 27 days post
HSCT. 3 (23%) patients have mixed donor chimerism with 60%
donor T cells. Ten (80%) patients are alive with resolution of enter-
opathy and have discontinued immunosuppression, one remains an
inpatient after HSCT about 100 days ago. 5/13 (38%) patients had
no graft versus host disease (GvHD) and 6/13 (46%) had only grade
II-III skin GvHD. Two (15%) died from complications related to
treatment of grade III skin and gut GvHD.
Conclusion: HSCT can be curative in patients with severe complex
autoimmune enteropathy. GvHD is a common significant complica-
tion which can be life threatening.71
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Objective: To examine the feasibility, safety and efficacy of he-
matopoietic stem cell transplantation (HSCT) in high-risk pedi-
atric and adult patients with chronic granulomatous disease
(CGD) using a low-toxicity conditioning regimen based on
half-dosed (50-60%) Busulfan, full-dose Fludarabine and in-vivo
T-cell depletion.
Patients andMethods: 11 CGD patients (5, 7, 12, 13, 17, 18, 20, 23,
29, 35 and 39 ys; n5 8 gp91-phox, n5 2 p22-phox and n5 1 p47
phox deficient) are described. All patients were therapy-refractory
to conventional treatment suffering from infectious and/or inflam-
matory complications at HSCT, e.g. colitis, active infection (Asper-
gillus, Neisseria, Actinomyces, Staph. aureus) or had former lung
aspergillosis. Stem cell donors consisted of 5 matched sibling, 4
MUD (10/10) and 2 MMUD (9/10) donors. Conditioning included
180 mg/qm Fludarabine (d -8 to -3), oral/iv. Busulfan (6.4-12 mg/
kg; d -4 to -2; in pediatric patients with adjusted Busulfan kinetics)
and Antithymocyte-Globulin Fresenius (4  10 mg/kg; d -4 to -1).
In 4 patients (5, 7, 12 and 17 ys) receiving MUD or MMUD trans-
plants, ATG-Fresenius was replaced by 0.5 mg/kg Alemtuzumab
(Campath IH) (d -8 to -6). As stem cell source, bone marrow (2.3
to 6.0  10 6 CD34/kg) was used in the majority of cases (n5 10),
S182 Oral Presentationsonly one patient received unrelated PBSC (5  10 6 CD34/kg).
GVHD-prophylaxis comprised Cyclosporine A (CSA) and Myco-
phenolate-Mofetil (MMF). MMF (1200 mg/qm) was administered
until d +100 and tapered thereafter. Two patients received MTX in-
stead of MMF.
Results: The early course after HSCT was uneventful. No acute
GHVD was encountered. No infectious or inflammatory flare
ups were observed. The hematological reconstitution with neutro-
phil (d +19 to +26) and platelet engraftment (d +21 to +22) was in
time. Six to 63 (median 36) months after HSCT, 10 patients are
alive and well (91%) with (95-100%) donor chimerism and stable
hematopoiesis. NBT- and DHR-tests are normalized (95-98%).
All active inflammatory and infectious foci are cured. One adult pa-
tient fathered a child after successful HSCT. One adult patient who
had suffered from severe active therapy-refractory bilateral Asper-
gillosis at transplant and had received a MUD CMV negative
PBSC died at day +150 due to pulmonary failure and endogenous
CMV reactivation.
Conclusion: This modified reduced intensity regimen is efficacious
and well-tolerated in both pediatric and adult high-risk CGD-
patients.72
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Objective: The optimal conditioning regimen for hematopoietic
stem cell transplantation (HSCT) in children with primary immuno-
deficiency diseases is currently unknown. Reduced-intensity condi-
tioning (RIC) concepts allow the inclusion of patients with severe
co-morbidities in transplantation concepts. Here we describe our re-
sults using fludarabine-based RIC regimen for the treatment of pe-
diatric patients with primary immunodeficiency.
Methods: Twenty one patients (8 female, 13 male) with primary
immunodeficiency underwent HSCT using RIC regimen.
Median age at HSCT was 28 months (range: 4 months-14
years).The preparative regimen consisted of fludarabine, melpha-
lan and antithymocyte globulin. 8 patients received stem cell
from healthy full HLA-matched siblings, 7 patients from HLA
matched other relative (four patients from parents, two patients
from grand father and one patient from uncle), 3 patient from
their haploidentical parents and 3 patients from unrelated cord
blood. The graft source was bone marrow in 7 patients, periph-
eral blood stem cells in 11 patients and in 3 patients from cord
blood. The primary immunodeficiencies in these children in-
cluded Leukocyte Adhesion Deficiency type one in 11, Wiskott
Aldrich Syndrome in 3, Griscelli syndrome in 2, Familial Eryth-
rophagocytic Lymphohistiocytosis in 2, severe combined immu-
nodeficiency in 1, Chediak-higashi in 1, and primary CD4
deficiency in 1.For graft-versus-host disease (GVHD) prophy-
laxis, we used Cyclosporine and Methylprednisolone.
Results: All patients except one engrafted. At a median follow-up of
3 months (range, 1-32 months), 18 (85.7%) patients are alive with
sustained engraftment and without recurrent infection, one patient
who not engrafted is alive with uncontrolled disease and two patients
died. 7 patients developed grade II-IV acute GVHD and 2 developed
limited chronic GVHD.
Among the two dead patients, one of them died from acute
GVHD 30 days after transplantation and the other from aspiration
pneumonia 66 days after transplantation which not related to trans-
plantation. These two dead patients received stem cell from their
haploidentical parents.
Conclusions: These data indicate HSCT following RIC regimen
can be used for treatment of primary immunodeficiency with well
tolerance and low transplant related mortality. When a related hap-
loidentical donor is used, the survival rate is lower than that of pa-
tients receiving HSCT from either an HLA-matched related or
a mismatched HLA-unrelated cords.73
PERFORIN DEPENDENT CYTOTOXICITY REGULATES THE IMMUNE RE-
SPONSE IN TRANS: HOWMUCH DONOR CHIMERISM IS ENOUGH TO PRO-
TECT FROM RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
(HLH) AFTER HCT?
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Genetic defects of perforin-dependent cytotoxicity underlie
HLH, a disorder of abnormal immune activation. Allogeneic HCT
can provide a definitive cure for HLH because it corrects these
defects. However, HCT may be complicated by the development
of mixed chimerism after transplantation. There continues to be
significant uncertainty regarding the need for repeat HCT in this
situation. Based on the experience of very limited numbers of
patients, it is thought that relatively small amounts of donor
chimerism are sufficient to protect patients from HLH recurrence
post HCT. We have utilized a murine model of HLH to determine
whether normal cytotoxic function in only a fraction of relevant
hematopoietic or immune cells may restore normal immune
regulation.
Perforin deficient (prf-/-) mice were lethally irradiated and
reconstituted with bone marrow from either wild type (WT),
prf-/-, or other immunodeficient donors. In parallel experiments,
WT or prf-/- T cells were transferred into cyclophosphamide condi-
tioned prf-/- mice. After establishment of bone marrow or T cell
grafts, prf-/- mice were challenged with viral infection and their im-
mune responses were quantitated.
Hematopoietic reconstitution of prf-/- mice with WT bone
marrow reestablished a normal pattern of cytokine production, T
cell activation, and antigen presentation after LCMV infection. As
the fraction of WT chimerism dropped below 10%, however, this
pattern reverted to that seen in prf-/- mice. Complementation
studies demonstrated that though NK cells may play a modest role
in controlling the immune response, reconstitution of normal per-
forin expression in T cells was critical (and sufficient) to reestablish
normal immune regulation. Transfer of purified WT CD8 T cells
alone was also sufficient to reconstitute normal immune responses,
if WT T cell engraftment exceeded 10%.
Because reconstitution of normal perforin expression in a minor
fraction (approximately 10%) of relevant cells is sufficient to reestab-
lish normal immune responsiveness in vivo, we conclude that per-
forin-dependent immunoregulation functions in trans, and that
CD8 T cells are the principle cell population exerting this effect.
These data suggest that donor chimerism of .10% should be suffi-
cient to protect patients from HLH recurrence post HCT, particu-
larly if T cells are of donor origin. These studies also suggest
a minimum target for successful gene therapy of HLH.
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ADOPTIVE IMMUNOTHERAPY AFTER UMBILICAL CORD BLOOD (UCB)
TRANSPLANTATION: MANUFACTURING AND ANALYSIS OF CD19-SPE-
CIFIC UCB-DERIVED T-CELLS FROM SCANT NUMBERS OF UCB MONONU-
CLEAR CELLS
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The rapid procurement, lower risk of graft-versus-host-disease
(GvHD), and the ability to undertake transplantation across
HLA disparities make umbilical cord blood (UCB) an attractive
stem-cell source. Adoptive transfer of tumor-specific T cells after
UCB transplantation (UCBT) is constrained by the functionally
naı¨ve UCB T cells and lack of ability to obtain additional cells.
We have previously shown that the specificity of T cells can be
redirected for CD19 using a chimeric antigen receptor (CAR)
independent of major histocompatibility complex. We have identi-
fied a source of clinical-grade UCB that may be used for
manufacturing without having to reduce the cell dose available
for transplantation. In our laboratory, after UCB units are washed
for clinical infusion, the supernatant is refrozen, and contains small
